Market Place
Sourcing Support
PharmaTher Updates on FDA NDA for Ketamine
26 Nov 2024 //
GLOBENEWSWIRE
PharmaTher Updates on FDA NDA for Ketamine
19 Nov 2024 //
GLOBENEWSWIRE
PharmaTher Granted FDA Clarification for Ketamine NDA
13 Nov 2024 //
GLOBENEWSWIRE
PharmaTher Receives FDA Response for Ketamine Application
23 Oct 2024 //
GLOBENEWSWIRE
PharmaTher Announces Update on FDA NDA for Ketamine
04 Sep 2024 //
GLOBENEWSWIRE
PharmaTher FDA Approval Goal Date For Ketamine ANDA
10 May 2024 //
GLOBENEWSWIRE
PharmaTher Updates Ketamine ANDA Priority Review Status
18 Apr 2024 //
GLOBENEWSWIRE
PharmaTher Provides Update on Ketamine ANDA Priority Application
16 Apr 2024 //
GLOBENEWSWIRE
Sairiyo Advances Clinical Development of Patented Reformulated Cepharanthine
21 Feb 2024 //
GLOBENEWSWIRE
PharmaTher Provides Update of its Priority Original Abbreviated NDA for Ketamine
12 Feb 2024 //
GLOBENEWSWIRE
PharmaTher Provides Update for Expected FDA Approval of Ketamine
10 Jan 2024 //
GLOBENEWSWIRE
PharmaTher Announces FDA Acceptance, As a Priority Abbreviated NDA, for KETARX
27 Sep 2023 //
GLOBENEWSWIRE
PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX
06 Sep 2023 //
GLOBENEWSWIRE
PharmaTher Holdings Provides Corporate Update
12 Jun 2023 //
GLOBENEWSWIRE
PharmaTher Announces Update of Type C Meeting with the FDA for KETARX
29 Mar 2023 //
GLOBENEWSWIRE
PharmaTher Submits FDA Package to Discuss 505(b)(2) Pathway for NDA of KETARX
07 Feb 2023 //
GLOBENEWSWIRE
Revive Enters into Research Collaboration Agreement with PharmaTher
03 Feb 2023 //
GLOBENEWSWIRE
PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX
02 Feb 2023 //
GLOBENEWSWIRE
PharmaTher Submits FDA Meeting Package to Discuss Phase 3 Program for KETARX
01 Feb 2023 //
GLOBENEWSWIRE
PharmaTher Submits for FDA Orphan Drug Designation for Ketamine
18 Jan 2023 //
GLOBENEWSWIRE
PharmaTher Holdings Provides Update for KETARX Development Programs
11 Jan 2023 //
GLOBENEWSWIRE
PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine
15 Dec 2022 //
GLOBENEWSWIRE
PharmaTher Announces Poster Presentation +ve Efficacy & Safety Data from Ph1/2
14 Nov 2022 //
GLOBENEWSWIRE
PharmaTher Enters into Exclusive Option Agreement with Case Western University
01 Nov 2022 //
GLOBENEWSWIRE
PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine
05 Oct 2022 //
GLOBENEWSWIRE
PharmaTher Announces Late-Breaking Presentation of +ve Efficacy & Safety Data
16 Sep 2022 //
GLOBENEWSWIRE
PharmaTher Announces Completion of IND-Enabling Study with KETARX™
07 Sep 2022 //
GLOBENEWSWIRE
PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine
13 Jul 2022 //
GLOBENEWSWIRE
PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch
29 Jun 2022 //
GLOBENEWSWIRE
PharmaTher Announces Positive Results from Study of KETABET for Depression
07 Jun 2022 //
GLOBENEWSWIRE
PharmaTher grows ketamine portfolio with on-body injector deal
27 May 2022 //
FIERCEPHARMA
PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device
25 May 2022 //
GLOBENEWSWIRE
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation
12 Apr 2022 //
GLOBENEWSWIRE
PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine
23 Mar 2022 //
GLOBENEWSWIRE
Revitalist and PharmaTher Collaborate for Ketamine Treatment Protocols
01 Mar 2022 //
BUSINESSWIRE
PharmaTher Announces FDA Approval of IND Application for Ketamine to Treat ALS
12 Jan 2022 //
GLOBENEWSWIRE
PharmaTher Announces Publication of Research Data for KETABET™
04 Jan 2022 //
GLOBENEWSWIRE
PharmaTher Provides Update on Product Pipeline and Expected Milestones for 2022
21 Dec 2021 //
GLOBENEWSWIRE
PharmaTher Enters Into Process Development Agreement With LTS LOHMANN
20 Dec 2021 //
GLOBENEWSWIRE
PharmaTher Announces Positive Research Results for LSD Microneedle Patch
14 Dec 2021 //
GLOBENEWSWIRE
PharmaTher Applies for FDA ODD for Ketamine in Status Epilepticus
24 Nov 2021 //
GLOBENEWSWIRE
PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch
11 Nov 2021 //
GLOBENEWSWIRE
PharmaTher, Revive Collaborate for Development of Psilocybin Microneedle Patch
03 Nov 2021 //
GLOBENEWSWIRE
PharmaTher Provides Research Update on Microneedle Patch Delivery Technologies
01 Nov 2021 //
GLOBENEWSWIRE
PharmaTher Provides Business Update and Releases Financial Results
27 Oct 2021 //
GLOBENEWSWIRE
Alcami, PharmaTher Enter Manufacturing Agreement
25 Oct 2021 //
CONTRACTPHARMA
PharmaTher Engages Alcami for Clinical and Commercial MFG of Novel Ketamine
19 Oct 2021 //
GLOBENEWSWIRE
PharmaTher Granted FDA Orphan Drug Designation For Ketamine
13 Oct 2021 //
GLOBENEWSWIRE
PharmaTher Initiates Phase 2 Clinical Trial of Ketamine of Parkinson’s Disease
06 Oct 2021 //
GLOBENEWSWIRE
PharmaTher Announces Closing of CAD$10 Million Private Placement
28 Sep 2021 //
GLOBENEWSWIRE
PharmaTher Announces CAD$10 Million Private Placement With Investors
24 Sep 2021 //
GLOBENEWSWIRE
PharmaTher Provides Business Highlights and Releases Annual Financials
07 Sep 2021 //
GLOBENEWSWIRE
PharmaTher Granted FDA Orphan Drug Designation For Ketamine
04 Aug 2021 //
GLOBENEWSWIRE
PharmaTher Expand Psychedelic Patent with Filing of U.S. Patent Application
21 Jul 2021 //
GLOBENEWSWIRE
PharmaTher To Participate in Grizzle Psychedelics Con
28 Jun 2021 //
GLOBENEWSWIRE
PharmaTher To Present At The H.C. Wainwright Psychedelics Conference
16 Jun 2021 //
GLOBENEWSWIRE
PharmaTher Files Pre-IND Meeting Request For KETABET
15 Jun 2021 //
GLOBENEWSWIRE
PharmaTher Provides Research and Development Update and Milestones for 2021
10 Jun 2021 //
GLOBENEWSWIRE
PharmaTher Collaborates with MediSynergics to Develop Patented Ketamine
27 May 2021 //
GLOBENEWSWIRE
